Tobin C. Schilke
2018 - Revance Therapeutics
In 2018, Tobin C. Schilke earned a total compensation of $2M as Chief Financial Officer at Revance Therapeutics.
Compensation breakdown
| Bonus | $25,000 |
|---|---|
| Option Awards | $1,434,350 |
| Salary | $64,644 |
| Stock Awards | $449,280 |
| Other | $233 |
| Total | $1,973,507 |
Schilke received $1.4M in option awards, accounting for 73% of the total pay in 2018.
Schilke also received $25K in bonus, $64.6K in salary, $449.3K in stock awards and $233 in other compensation.
Rankings
In 2018, Tobin C. Schilke's compensation ranked 5,822nd out of 14,244 executives tracked by ExecPay. In other words, Schilke earned more than 59.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,822 out of 14,244 | 59th |
Division Manufacturing | 2,207 out of 5,758 | 62nd |
Major group Chemicals And Allied Products | 819 out of 2,119 | 61st |
Industry group Drugs | 685 out of 1,808 | 62nd |
Industry Pharmaceutical Preparations | 532 out of 1,382 | 62nd |
Source: SEC filing on March 25, 2019.
Schilke's colleagues
We found six more compensation records of executives who worked with Tobin C. Schilke at Revance Therapeutics in 2018.
2018
L Browne
Revance Therapeutics
Chief Executive Officer
2018
Caryn McDowell
Revance Therapeutics
General Counsel
2018
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
2018
Todd Zavodnick
Revance Therapeutics
Former Chief Commercial Officer and President, Aesthetics & Therapeutics
2018
Lauren Silvernail
Revance Therapeutics
Chief Financial Officer
2018
Cyril Allouche
Revance Therapeutics
Former Head of Finance and Corporate Controller, Principal Accounting Officer
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019